Yahoo Finance Video Pfizer’s Covid-19 vaccine is more than 90% effective Mon, November 9, 2020, 2:17 PM GMT
Vaccine developer Pfizer and German partner BioNTech’s coronavirus vaccine is more than 90% effective. Dr. Dara Kass, Yahoo Medical Contributor & Columbia University Associate Professor of Emergency Medicine shares the details. Video Transcript
JULIE HYMAN: Now let's get back to the actual news here on Pfizer and just get a little more detail on what all of this could mean. We've already been hearing various comments from President Trump who tweeted this morning about the news. He said, the stock market's a big vaccine coming soon, report 90% effective, such great news.
And Joe Biden, the president-elect, who as we mentioned, is announcing a coronavirus task force, he came out with a statement on it. And he said, this is good news, but his statement on it was less effusive. He said, Americans are going to have to rely on masking, distancing, contact tracing, handwashing, and other measures to keep themselves safe well into next year. Today's news is great news, but it doesn't change that fact.
All right, let's bring in Dr. Dara Kass now. She is Yahoo Medical Contributor and Columbia University Associate Professor of Emergency Medicine. And you just need to unmute yourself, sorry, Dr. Kass. So I would ask, I guess, first of all, about how long it's going to take to, you know-- this has not been approved yet, this is a good step, but it's not approval. So what can we expect now in terms of the timeline sort of to Joe Biden's point there about, you know, we still have a ways to go before this is gone?
DARA KASS: Yeah, I think that's actually a really good opportunity to think about leadership style and what it means in the middle of evolving information. This information is excellent. It's not just good, it's excellent. It means that 90% of the people who are novel to the virus, who had no exposure, were protected by the combination of the two vaccines that they received, which is extraordinary. It's also an interim study, meaning that it has-- it's the data in the middle of their phase three trial, and that we expect them to hopefully have enough data at the completion, somewhere around November, December, to apply for this emergency use authorization. ref yahoo,
Australians to get coronavirus vaccine from March, health minister says
Australians will get a coronavirus vaccine from March, Health Minister Greg Hunt has confirmed. Mr Hunt said Australia is "well placed" to give the green light to at least two of the four vaccines the country has bought. "We are on track to deliver vaccines to Australians, commencing March of 2021," he said. "We won't be out of this until we have a nation which has had a full vaccination programme
"But we are on track to deliver those vaccines. It's well ahead of expectations." He said approvals on the first two vaccines are being fast tracked and could be given in January "with an absolute premium on safety"
Australia has bought 134.8 million vaccines in total - enough for three times the population
Mercedes_00: Australians to get coronavirus vaccine from March, health minister says
Australians will get a coronavirus vaccine from March, Health Minister Greg Hunt has confirmed. Mr Hunt said Australia is "well placed" to give the green light to at least two of the four vaccines the country has bought. "We are on track to deliver vaccines to Australians, commencing March of 2021," he said. "We won't be out of this until we have a nation which has had a full vaccination programme
"But we are on track to deliver those vaccines. It's well ahead of expectations." He said approvals on the first two vaccines are being fast tracked and could be given in January "with an absolute premium on safety"
Australia has bought 134.8 million vaccines in total - enough for three times the population
Well, I'll probably be asked to take the vaccine in the first group, especially if I want to start working in the field full time again and board planes to other countries... without it, there will be an insurance liability and I'll be limited as to what I can do until I get one. But, it will depend on which vaccine is offered in the end including possible side effects and the reaction it has... some people will have to get allergy tested. Working alone locally is still an option and yet I still haven't decided. I think it's more likely the UK and Australia will be using the Oxford Astra Zeneca vaccine although they've had some issues with it which is more of a shield and Phase 3 in testing will be over by December 2020.
GeneralBeacon: Well, I'll probably be asked to take the vaccine in the first group, especially if I want to start working in the field full time again and board planes to other countries... without it, there will be an insurance liability and I'll be limited as to what I can do until I get one. But, it will depend on which vaccine is offered in the end including possible side effects and the reaction it has... some people will have to get allergy tested. Working alone locally is still an option and yet I still haven't decided. I think it's more likely the UK and Australia will be using the Oxford Astra Zeneca vaccine although they've had some issues with it which is more of a shield and Phase 3 in testing will be over by December 2020.
Of course, the UK is in line for the Pfizer vaccine, and all are delivered free in the UK under the NHS.
Pfizer breakthrough - and who will get it first?
A vaccine against coronavirus could help beat lockdown and help life get back to normal - pharmaceutical giant Pfizer believes it's close if not imminent,
Pfizer's COVID-19 Vaccine Won't Be at Local Pharmacy Any Time Soon
Pfizer (PFE) and BioNTech (BNTX) need to get regulators to sign off on the shot before it can start shipping vaccines to those considered most in need by government. Healthcare workers and people living in nursing homes will likely top that list.
But the vaccine's complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.
The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below.
"The cold chain is going to be one of the most challenging aspects of delivery of this vaccination," said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security.
"This will be a challenge in all settings because hospitals even in big cities do not have storage facilities for a vaccine at that ultra-low temperature."
Indeed, one of the most prestigious U.S. hospitals, the Mayo Clinic in Rochester, Minnesota, said it does not currently have that capability.
"We're talking about a vaccine that needs storage at minus 70 or 80. That's a tremendous logistical issue not only in the U.S. but outside the Western world," said Dr Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic.
"We're a major medical center and we don't have storage capacity like this. That will be true for everybody. This is a logistical obstacle."
Pfizer spokeswoman Kim Bencker said the company was working closely with the U.S. government and state officials on how to ship the vaccine from its distribution centers in the United States, Germany and Belgium around the globe.
The detailed plan includes using dry ice to transport frozen vaccine vials by both air and land at their recommended temperatures for up to 10 days, she said.................
GeneralBeacon: Well, I'll probably be asked to take the vaccine in the first group, especially if I want to start working in the field full time again and board planes to other countries... without it, there will be an insurance liability and I'll be limited as to what I can do until I get one. But, it will depend on which vaccine is offered in the end including possible side effects and the reaction it has... some people will have to get allergy tested. Working alone locally is still an option and yet I still haven't decided. I think it's more likely the UK and Australia will be using the Oxford Astra Zeneca vaccine although they've had some issues with it which is more of a shield and Phase 3 in testing will be over by December 2020.
You'll be asked to take it first because you're in your 70's
Pfizer's COVID-19 Vaccine Won't Be at Local Pharmacy Any Time Soon
Pfizer (PFE) and BioNTech (BNTX) need to get regulators to sign off on the shot before it can start shipping vaccines to those considered most in need by government. Healthcare workers and people living in nursing homes will likely top that list.
But the vaccine's complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.
The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below.
"The cold chain is going to be one of the most challenging aspects of delivery of this vaccination," said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security.
"This will be a challenge in all settings because hospitals even in big cities do not have storage facilities for a vaccine at that ultra-low temperature."
Indeed, one of the most prestigious U.S. hospitals, the Mayo Clinic in Rochester, Minnesota, said it does not currently have that capability.
"We're talking about a vaccine that needs storage at minus 70 or 80. That's a tremendous logistical issue not only in the U.S. but outside the Western world," said Dr Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic.
"We're a major medical center and we don't have storage capacity like this. That will be true for everybody. This is a logistical obstacle."
Pfizer spokeswoman Kim Bencker said the company was working closely with the U.S. government and state officials on how to ship the vaccine from its distribution centers in the United States, Germany and Belgium around the globe.
The detailed plan includes using dry ice to transport frozen vaccine vials by both air and land at their recommended temperatures for up to 10 days, she said.................
I'm glad you copy and pasted in red, it helped me to understand it more
tomcatty: I agree with you Aragorn, my God the sky is falling
It is good news but as Conrad posted there will be serious logistics problems with the Pfizer/Biontech vaccine when it comes to distribution due to the storage temperature issues. Nothing that can't be overcome, especially in 1st world countries, but it will probably delay distribution and have effects on administering.
Pfizer's COVID-19 Vaccine Won't Be at Local Pharmacy Any Time Soon
Pfizer (PFE) and BioNTech (BNTX) need to get regulators to sign off on the shot before it can start shipping vaccines to those considered most in need by government. Healthcare workers and people living in nursing homes will likely top that list.
But the vaccine's complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.
The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below.
"The cold chain is going to be one of the most challenging aspects of delivery of this vaccination," said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security.
"This will be a challenge in all settings because hospitals even in big cities do not have storage facilities for a vaccine at that ultra-low temperature."
Indeed, one of the most prestigious U.S. hospitals, the Mayo Clinic in Rochester, Minnesota, said it does not currently have that capability.
"We're talking about a vaccine that needs storage at minus 70 or 80. That's a tremendous logistical issue not only in the U.S. but outside the Western world," said Dr Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic.
"We're a major medical center and we don't have storage capacity like this. That will be true for everybody. This is a logistical obstacle."
Pfizer spokeswoman Kim Bencker said the company was working closely with the U.S. government and state officials on how to ship the vaccine from its distribution centers in the United States, Germany and Belgium around the globe.
A USARMY General has been working the cold storage issue, Also the logistic. He was just questioned on both.....says they are ready transport and to store the vaccine when it is released.
They can use dry ice for the storage. In the US...we often get food deliveries in dry ice and foam containers. Suspect it is going to be the same here.
Aragorn11: It is good news but as Conrad posted there will be serious logistics problems with the Pfizer/Biontech vaccine when it comes to distribution due to the storage temperature issues. Nothing that can't be overcome, especially in 1st world countries, but it will probably delay distribution and have effects on administering.
Report threads that break rules, are offensive, or contain fighting. Staff may not be aware of the forum abuse, and cannot do anything about it unless you tell us about it. click to report forum abuse »
If one of the comments is offensive, please report the comment instead (there is a link in each comment to report it).
Pfizer’s Covid-19 vaccine is more than 90% effective
Mon, November 9, 2020, 2:17 PM GMT
Vaccine developer Pfizer and German partner BioNTech’s coronavirus vaccine is more than 90% effective. Dr. Dara Kass, Yahoo Medical Contributor & Columbia University Associate Professor of Emergency Medicine shares the details.
Video Transcript
JULIE HYMAN: Now let's get back to the actual news here on Pfizer and just get a little more detail on what all of this could mean. We've already been hearing various comments from President Trump who tweeted this morning about the news. He said, the stock market's a big vaccine coming soon, report 90% effective, such great news.
And Joe Biden, the president-elect, who as we mentioned, is announcing a coronavirus task force, he came out with a statement on it. And he said, this is good news, but his statement on it was less effusive. He said, Americans are going to have to rely on masking, distancing, contact tracing, handwashing, and other measures to keep themselves safe well into next year. Today's news is great news, but it doesn't change that fact.
All right, let's bring in Dr. Dara Kass now. She is Yahoo Medical Contributor and Columbia University Associate Professor of Emergency Medicine. And you just need to unmute yourself, sorry, Dr. Kass. So I would ask, I guess, first of all, about how long it's going to take to, you know-- this has not been approved yet, this is a good step, but it's not approval. So what can we expect now in terms of the timeline sort of to Joe Biden's point there about, you know, we still have a ways to go before this is gone?
DARA KASS: Yeah, I think that's actually a really good opportunity to think about leadership style and what it means in the middle of evolving information. This information is excellent. It's not just good, it's excellent. It means that 90% of the people who are novel to the virus, who had no exposure, were protected by the combination of the two vaccines that they received, which is extraordinary. It's also an interim study, meaning that it has-- it's the data in the middle of their phase three trial, and that we expect them to hopefully have enough data at the completion, somewhere around November, December, to apply for this emergency use authorization.
ref yahoo,